Route of Administration Clause Samples

The Route of Administration clause defines the specific method or pathway by which a drug, medication, or therapeutic product must be delivered to a patient. This clause typically specifies whether the product is to be administered orally, intravenously, topically, or by another route, and may include requirements for dosage form or delivery devices. By clearly outlining the permitted or required administration route, the clause ensures proper use of the product, supports regulatory compliance, and helps prevent misuse or errors in treatment.
POPULAR SAMPLE Copied 1 times
Route of Administration. Check appropriate box. If “other” is chosen please specify. • Enter the strength (e.g. 100 mg, 5 ml) and the dose form (e.g. tablet, capsule, injection).
View SourceView Similar (3)
Route of Administration. Dose Strength/Form
View SourceView Similar (3)
Route of Administration. For the routes of administration the differences encountered during the GAP analysis are the same as for Dose Form:  EPSOS uses this value set in the version 2010 of EDQM standard where EMA use the same value set in the latest EDQM version (2014).  EPSOS use the lower case for the description (less than first letter) where EMA use always UPPERCASE values. Eg: EPSOS: “Auricular use”; EMA: “AURICULAR USE”;  EMA has the concept of proposed terms which are terms registered in EMA database, but not approved yet. Some of these proposed terms are not in EDQM standards. In 6.2 the details of differences and the proposed harmonization are provided.
View Source
Route of Administration. Refer to MOP for detailed instructions for use in the package inserts.
View Source
Route of Administration. Presently most studies have focused on direct injection of TCAP into the brain using indwelling cannulae. Pilot studies indicate that intravenous injection is a viable method, although a full set of behavioural experiments to ascertain this have not been performed. In addition, subcutaneous injection has not been investigated. TCAP will be administered either as a single injection IV or SC to determine acute effects, or as one injection each day over five days to determine chronic actions. The acoustic startle response, elevated plus maze, swim test behaviour locomotion and body weight changes will be examined Nothing is presently known about the longevity of TCAP in vivo. A structural analysis of the peptide predicts that TCAP is modified for circulation in the blood stream. Two sets of experiments are designed to answer these questions. Synthetic TCAP will be incubated in rat plasma, and its breakdown by proteolytic enzymes will be determined by examining the loss of immunoreactive signal on a high resolution polyacrylamide gel using TCAP-specific antisera over a 2 to 8 hour period. The length of time will be based on its rate of breakdown in the first 1 to 2 hours of the study. This will allow us to understand the plasma component of TCAP degradation. Upon completion of the above experiments, TCAP will be injected intravenously into rats and the presence of TCAP in tissues and the brain will be examined by radioimmunoassay. TCAP expression
View Source

Related to Route of Administration

  • Mechanics of Administration (1) Except to the extent provided for in this Settlement Agreement, the mechanics of the implementation and administration of this Settlement Agreement shall be determined by the Courts on motions brought by Class Counsel.

  • Grant Administration Grantee shall use the Grant funds only for the activities described in the approved Scope of Work. Grantee shall maintain financial records relating to the receipt and expenditure of all Grant funds in accordance with the terms set forth under this Agreement for a period of seven (7) years starting on the first day after final payment under the Agreement.

  • Claims Administration An employee will be required to comply with any and all rules and regulations and/or limitations established by the carrier or applicable third party administrator and contained in the policy, and employees and their dependents shall look solely to such carrier or third party administration for the adjudication of the payment of any and all benefits claims.

  • ADMINISTRATION OF MEDICATION CONTRACTOR shall comply with the requirements of California Education Code section 49423 when CONTRACTOR serves a student that is required to take prescription and/or over-the-counter medication during the school day. CONTRACTOR may designate personnel to assist the student with the administration of such medication after the student’s parent(s) provides to CONTRACTOR: (a) a written statement from a physician detailing the type, administration method, amount, and time schedules by which such medication shall be taken; and (b) a written statement from the student’s parent(s) granting CONTRACTOR permission to administer medication(s) as specified in the physician’s statement. CONTRACTOR shall maintain, and provide to LEA upon request, copies of such written statements. CONTRACTOR shall maintain a written log for each student to whom medication is administered. Such written log shall specify the student’s name; the type of medication; the date, time, and amount of each administration; and the name of CONTRACTOR’s employee who administered the medication. CONTRACTOR maintains full responsibility for assuring appropriate staff training in the administration of such medication consistent with physician’s written orders. Any change in medication type, administration method, amount or schedule must be authorized by both a licensed physician and parent.

  • Function of Joint Health and Safety Committee All incidents involving aggression or violence shall be brought to the attention of the Joint Health and Safety Committee. The Employer agrees that the Joint Health and Safety Committee shall concern itself with all matters relating to violence to staff.